Dementia

New class of drug helps people with severe dementia and their careers

Published in Drug Week, October 10th, 2003

The major costs incurred by dementia are attributable to people who are severely affected by the disease; until recently the drugs available for treating dementia were effective only in mildly or moderately affected people.

Increasing evidence now shows, however, that new classes of drugs, such as the NMDA receptor antagonist memantine, can help patients with moderately severe to severe dementia.

The most recent evidence comes from a 166-patient study of people with dementia, known by doctors as the M-BEST trial (Benefit and Efficacy in Severely demented patients during Treatment with Memantine). This supports data from other studies carried out in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry